{"id":"https://openalex.org/W2565553650","doi":"https://doi.org/10.1212/wnl.86.16_supplement.i1.006","title":"In Synucleinopathies, Elevated Ratios of Cysteinyl-Dopamine:3,4-Dihydroxyphenylacetic Acid (DOPAC) in Cerebrospinal Fluid are Associated Specifically with Parkinsonism (I1.006)","display_name":"In Synucleinopathies, Elevated Ratios of Cysteinyl-Dopamine:3,4-Dihydroxyphenylacetic Acid (DOPAC) in Cerebrospinal Fluid are Associated Specifically with Parkinsonism (I1.006)","publication_year":2016,"publication_date":"2016-04-05","ids":{"openalex":"https://openalex.org/W2565553650","doi":"https://doi.org/10.1212/wnl.86.16_supplement.i1.006","mag":"2565553650"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.86.16_supplement.i1.006","doi":"https://doi.org/10.1212/wnl.86.16_supplement.i1.006","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.86.16_supplement.i1.006","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050003203","display_name":"David S. Goldstein","orcid":"https://orcid.org/0000-0002-5709-9940","observed_orcids":["https://orcid.org/0000-0002-5709-9940"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210110767","display_name":"National Institute of Neurological Disorders and Stroke","ror":"https://ror.org/01s5ya894","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210110767"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Goldstein","raw_affiliation_strings":["Clinical Neurocardiology Section, CNP/DIR/NINDS/NIH Bethesda MD United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Neurocardiology Section, CNP/DIR/NINDS/NIH Bethesda MD United States","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210110767"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057348787","display_name":"Courtney S. Holmes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Courtney Holmes","raw_affiliation_strings":["Bethesda MD United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bethesda MD United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042995179","display_name":"Irwin J. Kopin","orcid":"https://orcid.org/0000-0002-8234-870X","observed_orcids":["https://orcid.org/0000-0002-8234-870X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Irwin Kopin","raw_affiliation_strings":["Bethesda MD United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bethesda MD United States","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077449453","display_name":"Yehonatan Sharabi","orcid":"https://orcid.org/0000-0002-7566-988X","observed_orcids":["https://orcid.org/0000-0002-7566-988X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yehonatan Sharabi","raw_affiliation_strings":["Bethesda MD United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bethesda MD United States","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.21452198,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"86","issue":"16_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10919","display_name":"Deep Brain Stimulation and Movement Disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13481","display_name":"Neurological diseases and metabolism","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/synucleinopathies","display_name":"synucleinopathies","score":0.9789999723434448},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.7609999775886536},{"id":"https://openalex.org/keywords/multiple-system-atrophy","display_name":"multiple system atrophy","score":0.9269999861717224},{"id":"https://openalex.org/keywords/parkinsonism","display_name":"parkinsonism","score":0.8629999756813049},{"id":"https://openalex.org/keywords/dopac","display_name":"DOPAC","score":0.9380000233650208},{"id":"https://openalex.org/keywords/cerebrospinal-fluid-biomarkers","display_name":"cerebrospinal fluid biomarkers","score":0.9049999713897705},{"id":"https://openalex.org/keywords/dopamine-metabolism","display_name":"dopamine metabolism","score":0.6150000095367432},{"id":"https://openalex.org/keywords/oxidative-stress","display_name":"oxidative stress","score":0.7710000276565552},{"id":"https://openalex.org/keywords/aldehyde-dehydrogenase","display_name":"aldehyde dehydrogenase","score":0.9700000286102295},{"id":"https://openalex.org/keywords/catechol","display_name":"catechol","score":0.6769999861717224},{"id":"https://openalex.org/keywords/nigrostriatal-dopaminergic-neurons","display_name":"nigrostriatal dopaminergic neurons","score":0.8190000057220459},{"id":"https://openalex.org/keywords/msa-c","display_name":"MSA-C","score":0.5},{"id":"https://openalex.org/keywords/msa-p","display_name":"MSA-P","score":0.8180000185966492},{"id":"https://openalex.org/keywords/early-diagnosis","display_name":"early diagnosis","score":0.5440000295639038},{"id":"https://openalex.org/keywords/treatment-monitoring","display_name":"treatment monitoring","score":0.4429999887943268},{"id":"https://openalex.org/keywords/lipid-peroxidation","display_name":"lipid peroxidation","score":0.5950000286102295}],"concepts":[{"id":"https://openalex.org/C2776525014","wikidata":"https://www.wikidata.org/wiki/Q1531991","display_name":"Parkinsonism","level":3,"score":0.732958972454071},{"id":"https://openalex.org/C2779651940","wikidata":"https://www.wikidata.org/wiki/Q54196","display_name":"Cerebrospinal fluid","level":2,"score":0.7295684814453125},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.6894752979278564},{"id":"https://openalex.org/C2777440831","wikidata":"https://www.wikidata.org/wiki/Q2376264","display_name":"Synucleinopathies","level":5,"score":0.6288466453552246},{"id":"https://openalex.org/C2775841634","wikidata":"https://www.wikidata.org/wiki/Q903566","display_name":"Homovanillic acid","level":4,"score":0.5391438603401184},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.4155595302581787},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.40054851770401},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.39881110191345215},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.329847127199173},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.13500216603279114},{"id":"https://openalex.org/C2781449126","wikidata":"https://www.wikidata.org/wiki/Q288591","display_name":"Alpha-synuclein","level":4,"score":0.09953829646110535},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.08857885003089905},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0766330361366272},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.86.16_supplement.i1.006","doi":"https://doi.org/10.1212/wnl.86.16_supplement.i1.006","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.86.16_supplement.i1.006","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389467360","https://openalex.org/W2505865209","https://openalex.org/W2037507796","https://openalex.org/W4400157540","https://openalex.org/W2161756416","https://openalex.org/W2257400832","https://openalex.org/W3156730522","https://openalex.org/W2078684207","https://openalex.org/W1992925361","https://openalex.org/W2791928525"],"abstract_inverted_index":{"Objective:":[0],"We":[1],"assessed":[2],"whether":[3],"an":[4],"elevated":[5,261],"cysteinyl-dopamine:3,4-dihydroxyphenylacetic":[6],"acid":[7],"(DOPAC)":[8],"ratio":[9,228],"provides":[10],"a":[11,267,286],"specific":[12,268],"biomarker":[13,269],"of":[14,30,41,52,58,70,117,124,132,270,288],"parkinsonism":[15,83],"in":[16,24,62,65,75,110,145,176,187,194,223,239,249,256,259,276,291],"synucleinopathy":[17],"patients.":[18],"Background:":[19],"There":[20],"is":[21,79],"intense":[22],"interest":[23],"identifying":[25],"cerebrospinal":[26],"fluid":[27],"(CSF)":[28],"biomarkers":[29],"Parkinson\u2019s":[31],"disease":[32],"(PD),":[33],"for":[34],"early":[35],"diagnosis":[36],"and":[37,114,128,165,181,198,212,234,251,278],"to":[38,97,104,134,170,265],"track":[39],"effects":[40],"putative":[42],"treatments.":[43],"Nigrostriatal":[44],"dopamine":[45,91,133],"depletion":[46],"characterizes":[47],"PD.":[48],"Predictably,":[49],"CSF":[50,77,141,172,185,243,262,273],"levels":[51],"DOPAC,":[53,135],"the":[54,71,88,200,225],"main":[55],"neuronal":[56,89],"metabolite":[57],"dopamine,":[59],"are":[60,246,254],"decreased":[61,175,282],"PD,":[63,150],"even":[64],"patients":[66,148,152,159],"with":[67,82,149,153,160],"recent":[68],"onset":[69],"movement":[72],"disorder.":[73],"Whether":[74],"synucleinopathies":[76,260],"DOPAC":[78,99,173,186],"associated":[80],"specifically":[81],"has":[84],"been":[85],"unclear.":[86],"In":[87,196],"cytoplasm":[90],"not":[92,190],"only":[93],"undergoes":[94],"enzymatic":[95],"oxidation":[96,103],"form":[98,105],"but":[100,253],"also":[101],"spontaneous":[102],"5-S-cysteinyl-dopamine.":[106],"Theoretically,":[107],"oxidative":[108,289],"stress":[109],"nigrostriatal":[111,292],"dopaminergic":[112,293],"neurons":[113],"consequent":[115],"generation":[116],"lipid":[118],"peroxidation":[119],"products":[120],"could":[121],"decrease":[122,130],"activity":[123,284],"aldehyde":[125],"dehydrogenase":[126],"(ALDH)":[127],"thereby":[129],"conversion":[131],"while":[136],"increasing":[137],"cysteinyl-dopamine":[138],"formation.":[139],"Methods:":[140],"catechols":[142],"were":[143,204],"assayed":[144],"30":[146],"levodopa-untreated":[147],"35":[151],"probable":[154,161],"parkinsonian":[155],"MSA":[156,163],"(MSA-P),":[157],"12":[158],"cerebellar":[162],"(MSA-C)":[164],"33":[166],"controls.":[167],"Results:":[168],"Compared":[169],"controls,":[171],"was":[174,229,235],"PD":[177,197,250,277],"(p<0.0001),":[178],"MSA-P":[179,188,199,240,252,279],"(p<0.0001)":[180],"MSA-C":[182,224],"(p=0.007).":[183],"Mean":[184],"did":[189],"differ":[191],"from":[192],"that":[193,238],"MSA-C.":[195,257],"mean":[201,226],"cysteinyl-dopamine:DOPAC":[202,227,244,263,274],"ratios":[203,245,275],"more":[205],"than":[206,237],"twice":[207],"control":[208],"(0.14":[209],"\u00b1":[210,214,218,232],"0.02":[211,215],"0.13":[213],"vs.":[216],"0.05":[217],"0.01,":[219],"p<0.0001":[220],"each),":[221],"whereas":[222],"normal":[230,255],"(0.06":[231],"0.01)":[233],"less":[236],"(p=0.03).":[241],"Conclusions:":[242],"substantially":[247],"increased":[248],"Therefore,":[258],"seems":[264],"provide":[266],"parkinsonism.":[271],"High":[272],"might":[280],"reflect":[281],"ALDH":[283],"as":[285],"consequence":[287],"injury":[290],"terminals.":[294]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-01-06T00:00:00"}